Dividend
-
-
-
-
-
-
-
AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
-
-
-
-
-
-
-
AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS
-
-
-
-
-
-
-
Amgen (AMGN) Declares $2.52 Quarterly Dividend; 2.7% Yield
-
-
-
-
-
-
-
FDA approves Amgen's UPLIZNA for generalized myasthenia gravis
-
-
-
-
-
-
-
AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL
-
-
-
-
-
-
-
FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
-
-
-
-
-
-
-
AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS
-
452,000 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

